We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+47.82%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$808M
AUM Growth
+$260M
Cap. Flow
+$115M
Cap. Flow %
14.29%
Top 10 Hldgs %
40.15%
Holding
122
New
39
Increased
28
Reduced
16
Closed
27

Top Buys

Rank Stock Value
1
XENE icon
Xenon Pharmaceuticals
XENE
+$17.4M
2
VERA icon
Vera Therapeutics
VERA
+$16.7M
3
ONC
BeOne Medicines Ltd
ONC
+$13.2M
4
AUTL
Autolus Therapeutics
AUTL
+$11.4M
5
KURA icon
Kura Oncology
KURA
+$10.5M

Top Sells

Rank Stock Value
1
IMGN
Immunogen Inc
IMGN
+$41.6M
2
CBAY
Cymabay Therapeutics
CBAY
+$25.8M
3
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$18.9M
4
LIAN
LianBio American Depositary Shares
LIAN
+$16.9M
5
VKTX icon
Viking Therapeutics
VKTX
+$11.1M

Sector Composition

Rank Sector Weight
1 Healthcare 70.51%
2 Financials 0.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TNGX icon
76
Tango Therapeutics
TNGX
$4.34B
$1.19M 0.15%
150,274
-150,000
-50% -$1.61M
ZURA icon
77
Zura Bio
ZURA
$497M
$1.16M 0.14%
+450,009
New +$1.59M
TRML
78
DELISTED
Tourmaline Bio
TRML
$1.15M 0.14%
50,000
-18,081
-27% -$638K
TVTX icon
79
Travere Therapeutics
TVTX
$5.33B
$964K 0.12%
+125,000
New +$1.05M
TECX
80
Tectonic Therapeutic
TECX
$573M
$896K 0.11%
58,333
+16,666
+40% +$264K
ANVS icon
81
PUT
Annovis Bio
ANVS
$70.6M
$868K 0.11%
+72,900
New +$795K
RAPT
82
CALL
DELISTED
RAPT Therapeutics
RAPT
$539K 0.07%
+7,500
New +$1.04M
PMN icon
83
ProMIS Neurosciences
PMN
$109M
$508K 0.06%
10,638
– –
IMTXW
84
DELISTED
Immatics N.V. Warrants
IMTXW
$487K 0.06%
187,204
– –
QTTB icon
85
Q32 Bio
QTTB
$450M
$473K 0.06%
+27,777
New +$383K
CNTX icon
86
Context Therapeutics
CNTX
$56.4M
$454K 0.06%
328,817
– –
CBIO
87
PUT
Crescent Biopharma
CBIO
$602M
$427K 0.05%
+1,423
New +$425K
PASG icon
88
Passage Bio
PASG
$15.9M
$357K 0.04%
+13,213
New +$318K
AVTX icon
89
Avalo Therapeutics
AVTX
$976M
$218K 0.03%
+10,000
New +$53.9K
SAVAW
90
DELISTED
Cassava Sciences, Inc. Warrant
SAVAW
$97.5K 0.01%
+24,200
New +$145K
RCKTW icon
91
Rocket Pharmaceuticals Warrant
RCKTW
$320K
$22.4K ﹤0.01%
75,000
– –
ADCT icon
92
ADC Therapeutics
ADCT
$146M
– –
-1,013,540
Closed -$1.68M
ALKS icon
93
PUT
Alkermes
ALKS
$8.82B
– –
-27,000
Closed -$749K
ALLO icon
94
Allogene Therapeutics
ALLO
$601M
– –
-400,000
Closed -$1.28M
APLS
95
CALL
DELISTED
Apellis Pharmaceuticals
APLS
– –
-25,000
Closed -$1.5M
ARGX icon
96
argenx
ARGX
$57.4B
– –
-7,500
Closed -$2.85M
ASND icon
97
Ascendis Pharma A/S
ASND
$16.7B
– –
-20,000
Closed -$2.52M
AZN icon
98
AstraZeneca
AZN
$263B
– –
-30,000
Closed -$4.04M
BHVN icon
99
Biohaven
BHVN
$2.16B
– –
-20,866
Closed -$893K
CRNX icon
100
PUT
Crinetics Pharmaceuticals
CRNX
$8.86B
– –
-94,300
Closed -$3.36M
1 2 3
4
5

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
WPC
Waters Parkerson & Co New Orleans, Louisiana $1.95B AUM 15.9% 1-Year Est. Return

Affinity Asset Advisors's Q1 2024 Portfolio in Review

As of Q1 2024, Affinity Asset Advisors held 122 positions worth $808M, up 48% from $548M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Affinity Asset Advisors deployed $115M of net new capital in Q1 2024, opening 39 new positions and adding to 28 existing holdings. Its largest new stake was Vera Therapeutics: 470,000 shares worth $20.3M.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, down from 86% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Cerevel Therapeutics Holdings, Inc. Common Stock, an estimated $18.9M trimmed.

  • Affinity Asset Advisors's largest Q1 2024 buy was Vera Therapeutics: 470,000 shares worth $20.3M.
  • Affinity Asset Advisors added most to Xenon Pharmaceuticals in Q1 2024, an estimated $17.4M increase.
  • Affinity Asset Advisors's biggest Q1 2024 reduction was Cerevel Therapeutics Holdings, Inc. Common Stock, cutting an estimated $18.9M.
  • Affinity Asset Advisors fully exited Immunogen Inc in Q1 2024, selling an estimated $41.6M.
  • Affinity Asset Advisors's ten largest holdings make up 40% of its $808M portfolio in Q1 2024.
  • Affinity Asset Advisors opened 39 new positions and closed 27 in Q1 2024.
  • Affinity Asset Advisors's portfolio value rose 48% quarter-over-quarter to $808M.

Based on Affinity Asset Advisors's 13F filing for Q1 2024, filed 14 May 2024.